Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion

Open Access 25-03-2024 | Multiple Myeloma | ORIGINAL ARTICLE

Halofuginone Inhibits Osteoclastogenesis and Enhances Osteoblastogenesis by Regulating Th17/Treg Cell Balance in Multiple Myeloma Mice with Bone Lesions

Authors: Xiaofei Wu, Qiong Sun, Xiang Li, Lin Jiang, Li Chen

Published in: Indian Journal of Hematology and Blood Transfusion

Login to get access

Abstract

Evidences shows that T helper 17 (Th17) and regulatory T (Treg) cells imbalance plays a critical role in bone lesions of MM patients. Therefore, regulating the Th17/Treg imbalance may be beneficial for bone lesions in MM. Ten MM mice complicated with bone lesions were established and divided into the halofuginone (HF) group and the PBS group. After treatment, tibia and fibula from both groups were scanned by micro-CT. Osteoclasts and osteoblasts were validated by histochemical staining and ELISA. Th17 and Treg cells were tested by flow cytometry. The correlations between Th17/Treg cell ratio and osteoclasts, osteoblasts and bone remodeling were analyzed using the Spearman relative analysis. After treatment, mice in the HF group had an increase in trabecular bone volume fraction and thickened cortex, but a decrease in trabecular separation compared to mice in the PBS group.Tartrate-resistant acid phosphase (TRAP) + osteoclasts and its biomarker TRACP5b in serum were reduced, while alkaline phosphatase (ALP) + osteoblasts and its biomarker N-terminal propeptide of type 1precollagen (P1NP) in serum were accreted in the HF group. Th17/Treg cell ratio in halofuginone-treated mice was 0.85 ± 0.05, and was significantly lower than that in PBS-treated mice, which was 1.51 ± 0.03. In addition, it showed that the Th17/Treg cell ratio was significantly and positively associated with osteoclasts, but was significantly and negatively associated with osteoblasts and bone remodeling. Halofuginone plays a critical role in the amelioration bone lesions in MM, as it can inhibit osteoclastogenesis and enhance osteoblastogenesis by regulating the Th17/Treg cell balance.
Appendix
Available only for authorised users
Literature
1.
Guo N, Song Y, Zi F, Zheng J, Cheng J (2023) Abnormal expression pattern of lncRNA H19 participates in multiple myeloma bone disease by unbalancing osteogenesis and osteolysis. Int Immunopharmacol 119:110058CrossRefPubMed
2.
Huang B, Liu H, Chan S, Liu J, Gu J et al (2023) RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells. Med Oncol 40(4):115CrossRefPubMedPubMedCentral
3.
4.
O’Donnell EK, Raje NS (2017) Myeloma bone disease: pathogenesis and treatment. Clin Adv Hematol Oncol 15(4):285–295PubMed
5.
Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M et al (2010) Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A 107(11):5124–5129CrossRefPubMedPubMedCentral
6.
Tsubaki M, Seki S, Takeda T, Chihara A, Arai Y et al (2020) The HGF/Met/NF-κB pathway regulates RANKL expression in osteoblasts and bone marrow stromal cells. Int J Mol Sci 21(21):7905CrossRefPubMedPubMedCentral
7.
Simic MK, Mohanty ST, Xiao Y, Cheng TL, Taylor VE et al (2023) Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma. J Bone Miner Res 38(6):814–828CrossRefPubMed
8.
9.
Feng P, Yan R, Dai X, Xie X, Wen H, Yang S (2015) The alteration and clinical significance of Th1/Th2/Th17/Treg cells in patients with multiple myeloma. Inflammation 38(2):705–709CrossRefPubMed
10.
Ben Hmid A, Selmi O, Rekik R, Lamari H, Zamali I (2020) RORC overexpression as a sign of Th17 lymphocytes accumulation in multiple myeloma bone marrow. Cytokine 134:155210CrossRefPubMed
11.
Dong M, Zhang J, Chen Q, He D, Yan H et al (2022) High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients. Front Oncol 12:936670CrossRefPubMedPubMedCentral
12.
Ma T, Zhang Y, Zhou X, Xie P, Li J (2020) A unique role of T helper 17 cells in different treatment stages of multiple myeloma. Clin Lymphoma Myeloma Leuk 20(3):190–197CrossRefPubMed
13.
Gao R, Zhang W, Jiang Y, Zhai J, Yu J et al (2023) Eldecalcitol effectively prevents alveolar bone loss by partially improving Th17/Treg cell balance in diabetes-associated periodontitis. Front Bioeng Biotechnol 11:1070117CrossRefPubMedPubMedCentral
14.
Runyan CE, Liu Z, Schnaper HW (2012) Phosphatidylinositol 3-kinase and Rab5 GTPase inversely regulate the Smad anchor for receptor activation (SARA) protein independently of transforming growth factor-β1. J Biol Chem 287(43):35815–35824CrossRefPubMedPubMedCentral
15.
Ren X, Zhang M, Zhang W, Xie J, Luo H et al (2022) Yunnan Baiyao ameliorates rheumatoid arthritis in rats by shifting the Th17/Treg cell balance and preventing osteoclast differentiation. Evid Based Complement Alternat Med 2022:3764444CrossRefPubMedPubMedCentral
16.
Wang J, Wang B, Lv X, Wang Y (2020) Halofuginone functions as a therapeutic drug for chronic periodontitis in a mouse model. Int J Immunopathol Pharmacol 34:2058738420974893CrossRefPubMedPubMedCentral
17.
Park MK, Park JS, Park EM, Lim MA, Kim SM et al (2014) Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis. Arthritis Rheumatol 66(5):1195–1207CrossRefPubMed
18.
Leiba M, Jakubikova J, Klippel S, Mitsiades CS, Hideshima T et al (2012) Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol 157(6):718–731CrossRefPubMedPubMedCentral
19.
Sumitani Y, Hamba H, Nakamura K, Sadr A, Nikaido T, Tagami J (2018) Micro-CT assessment of comparative radiopacity of adhesive/composite materials in a cylindrical cavity. Dent Mater J 37(4):634–641CrossRefPubMed
20.
Zhang Q, Hu S, He Y, Song Z, Shen Y et al (2022) Monotropein protects against inflammatory bone loss and suppresses osteoclast formation and bone resorption by inhibiting NFATc1 via NF-κB and Akt/GSK-3β pathway. Nutrients 14(19):3978CrossRefPubMedPubMedCentral
21.
22.
Monnerat S, Refardt J, Potasso L, Meier C, Christ-Crain M (2023) An increase in plasma sodium levels is associated with an increase in osteoblast function in chronic SIAD. J Clin Endocrinol Metab 108(10):e1027–e1033CrossRefPubMedPubMedCentral
23.
Chen JR, Lazarenko OP, Blackburn ML, Chen JF, Randolph CE et al (2022) Nox4 expression in osteo-progenitors controls bone development in mice during early life. Commun Biol 5(1):583CrossRefPubMedPubMedCentral
24.
Carlson TJ, Pellerin A, Djuretic IM, Trivigno C, Koralov SB et al (2014) Halofuginone-induced amino acid starvation regulates Stat3-dependent Th17 effector function and reduces established autoimmune inflammation. J Immunol 192(5):2167–2176CrossRefPubMed
25.
Hou X, Zhou J, Yang R, Liu S, Bi M et al (2017) Effect of halofuginone on the pathogenesis of autoimmune thyroid disease in different mice models. Endocr Metab Immune Disord Drug Targets 17(2):141–148CrossRefPubMed
26.
Zhan W, Kang Y, Chen N, Mao C, Kang Y, Shang J (2017) Halofuginone ameliorates inflammation in severe acute hepatitis B virus (HBV)-infected SD rats through AMPK activation. Drug Des Devel Ther 11:2947–2955CrossRefPubMedPubMedCentral
27.
Bettelli E, Carrier Y, Gao W, Korn T, Strom TB et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235–238CrossRefPubMed
28.
Rossi M, Altomare E, Botta C, Gallo Cantafio ME, Sarvide S et al (2021) miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma. Leukemia 35(3):823–834CrossRefPubMed
29.
Ke D, Fu X, Xue Y, Wu H, Zhang Y et al (2018) IL-17A regulates the autophagic activity of osteoclast precursors through RANKL-JNK1 signaling during osteoclastogenesis in vitro. Biochem Biophys Res Commun 497(3):890–896CrossRefPubMed
30.
Wang Z, Wei Y, Lei L, Zhong J, Shen Y et al (2021) RANKL expression of primary osteoblasts is enhanced by an IL-17-mediated JAK2/STAT3 pathway through autophagy suppression. Connect Tissue Res 62(4):411–426CrossRefPubMed
31.
Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA (2006) Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 117(4):433–442CrossRefPubMedPubMedCentral
Metadata
Title
Halofuginone Inhibits Osteoclastogenesis and Enhances Osteoblastogenesis by Regulating Th17/Treg Cell Balance in Multiple Myeloma Mice with Bone Lesions
Authors
Xiaofei Wu
Qiong Sun
Xiang Li
Lin Jiang
Li Chen
Publication date
25-03-2024
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-024-01756-4
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits